{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T17:14:56Z","timestamp":1776618896774,"version":"3.51.2"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002879","name":"Canadian HIV Trials Network, Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["CTN PT038"],"award-info":[{"award-number":["CTN PT038"]}],"id":[{"id":"10.13039\/501100002879","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["Cell Therapy network"],"award-info":[{"award-number":["Cell Therapy network"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CanCURE 3.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite antiretroviral therapy (ART) controlling HIV viral replication, people with HIV (PWH) remain at risk for inflammatory non-AIDS comorbidities. Factors contributing to comorbidities in PWH on ART include spontaneous release of HIV products, CMV co-infection, microbial translocation, and gut dysbiosis, each driving systemic T-cell activation. In addition to ART, novel gut microbiota-modulating therapies could reduce epithelial gut permeability, microbial translocation, and immune activation. Fecal microbiota transplantation (FMT) from healthy volunteer is a promising therapy to counteract dysbiosis, protect from gut barrier damage, and lower systemic immune activation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Gutsy study is a single-blind, randomized, placebo-controlled clinical trial evaluating the effects of FMT in PWH on ART for more than 3\u00a0years, with a viral load below 50 copies\/mL, a CD4 count above 200 cells\/mL, and a CD4\/CD8 ratio below 1.0. All participants undergo a bowel cleanse before receiving FMT or placebo capsules. In the treatment group, 10 participants receive a bowel cleanse then two high doses of FMT delivered via 30 to 40 capsules twice, 3\u00a0weeks apart. The placebo group of 10 participants receive a bowel cleanse and capsules filled with microcrystalline cellulose for equivalence in weight and color, administered under the same time course. Peripheral blood mononuclear cells (PBMCs) and stool samples are collected at each visit: before bowel cleanse (baseline 1), before the first (baseline 2) and the 2nd (visit 4) FMT\/placebo, 6\u00a0weeks (visit 5) and 12\u00a0weeks (visit 6) after the first FMT\/placebo; colon biopsies are obtained at visits 3 and 6 in an optional sub-study. The primary objective is to assess the effect of FMT on plasma markers of gut epithelial permeability. Secondary objectives include microbial translocation, immune activation, and HIV latent reservoir biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>We hypothesize that large-dose FMT in capsules, but not placebo capsules, will increase the abundance of beneficial microbes in the gut of PWH on ART, leading to decreased gut damage markers and reduced immune activation. The results of the Gutsy pilot study will inform for the calculation of sample size of larger definitive randomized clinical trials assessing the influence of FMT on immune activation in PWH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov NCT06022406. Registered on 2024-08-01.\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT06022406?cond=HIV&amp;term=Gutsy&amp;rank=1\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT06022406?cond=HIV&amp;term=Gutsy&amp;rank=1<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-025-09345-0","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T08:45:55Z","timestamp":1765615555000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Fecal microbiota transplantation to reduce immune activation in ART-treated people with HIV with low CD4\/CD8 ratio: protocol for the single-blind, randomized, placebo-controlled Gutsy study (CIHR\/CTN PT038)"],"prefix":"10.1186","volume":"27","author":[{"given":"St\u00e9phane","family":"Isnard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina A.","family":"Berini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema Nair","family":"Parvathy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hansen","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orthy","family":"Aiyana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9na","family":"Royston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsoarello","family":"Mabanga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter L.","family":"Lakatos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talat","family":"Bessissow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina B.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Lebouch\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia T.","family":"Costiniuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Routy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9897-7589","authenticated-orcid":false,"given":"Jean-Pierre","family":"Routy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"key":"9345_CR1","doi-asserted-by":"crossref","unstructured":"Hsu DC, Sereti I. Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection. Drugs. 2016;76(5):533\u201349.","DOI":"10.1007\/s40265-016-0546-7"},{"key":"9345_CR2","doi-asserted-by":"crossref","unstructured":"Ramendra R, Isnard S, Lin J, Fombuena B, Ouyang J, Mehraj V, et al. Cytomegalovirus Seropositivity Is Associated With Increased Microbial Translocation in People Living With Human Immunodeficiency Virus and Uninfected Controls.\u00a0Clin Infect Dis. 2020;71(6):1438\u201346.","DOI":"10.1093\/cid\/ciz1001"},{"key":"9345_CR3","doi-asserted-by":"crossref","unstructured":"Caby F, Guiguet M, Weiss L, Winston A, Miro JM, Konopnicki D, et al. CD4\/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies.\u00a0Clin Infect Dis. 2021;73(1):50\u20139.","DOI":"10.1093\/cid\/ciab178"},{"key":"9345_CR4","doi-asserted-by":"crossref","unstructured":"Isnard S, Lin J, Bu S, Fombuena B, Royston L, Routy JP. Gut Leakage of Fungal-Related Products: Turning Up the Heat for HIV Infection. Front Immunol. 2021;12:656414.","DOI":"10.3389\/fimmu.2021.656414"},{"key":"9345_CR5","doi-asserted-by":"crossref","unstructured":"Dub\u00e9 M, Tastet O, Dufour C, Sannier G, Brassard N, Delgado GG, et al. Spontaneous HIV expression during suppressive ART is associated with the magnitude and function of HIV-specific CD4+ and CD8+ T cells. Cell Host & Microbe. 2023;31(9):1507\u20131522.e5.","DOI":"10.1016\/j.chom.2023.08.006"},{"key":"9345_CR6","doi-asserted-by":"crossref","unstructured":"Vujkovic-Cvijin I, Sortino O, Verheij E, Sklar J, Wit FW, Kootstra NA, et al. HIV-associated gut dysbiosis is independent of sexual practice and correlates with noncommunicable diseases. Nat Commun. 2020;11(1):2448.","DOI":"10.1038\/s41467-020-16222-8"},{"key":"9345_CR7","doi-asserted-by":"crossref","unstructured":"Vujkovic-Cvijin I, Somsouk M. HIV and the Gut Microbiota: Composition, Consequences, and Avenues for Amelioration. Curr HIV\/AIDS Rep. 2019;16(3):204\u201313.","DOI":"10.1007\/s11904-019-00441-w"},{"key":"9345_CR8","doi-asserted-by":"crossref","unstructured":"Ellis RJ, Iudicello JE, Heaton RK, Isnard S, Lin J, Routy JP, et al. Markers of Gut Barrier Function and Microbial Translocation Associate with Lower Gut Microbial Diversity in People with HIV. Viruses. 2021;13(10):1891.","DOI":"10.3390\/v13101891"},{"key":"9345_CR9","doi-asserted-by":"crossref","unstructured":"Isnard S, Fombuena B, Sadouni M, Lin J, Richard C, Routy B, et al. Circulating \u03b2- d -Glucan as a Marker of Subclinical Coronary Plaque in Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus. Open Forum Infect Dis. 2021;8(6):ofab109.","DOI":"10.1093\/ofid\/ofab109"},{"key":"9345_CR10","doi-asserted-by":"crossref","unstructured":"Marchetti G, Tincati C, Silvestri G. Microbial Translocation in the Pathogenesis of HIV Infection and AIDS. Clin Microbiol Rev. 2013;26(1):2\u201318.","DOI":"10.1128\/CMR.00050-12"},{"key":"9345_CR11","doi-asserted-by":"crossref","unstructured":"Isnard S, Royston L, Scott SC, Mabanga T, Lin J, Fombuena B, et al. Translocation of bacterial LPS is associated with self-reported cognitive abilities in men living with HIV receiving antiretroviral therapy. AIDS Res Ther. 2023;20(1):30.","DOI":"10.1186\/s12981-023-00525-z"},{"key":"9345_CR12","doi-asserted-by":"crossref","unstructured":"Takata H, Mitchell JL, Pacheco J, Pagliuzza A, Pinyakorn S, Buranapraditkun S, et al. An active HIV reservoir during ART is associated with maintenance of HIV-specific CD8+ T cell magnitude and short-lived differentiation status. Cell Host & Microbe. 2023;31(9):1494\u20131506.e4.","DOI":"10.1016\/j.chom.2023.08.012"},{"key":"9345_CR13","doi-asserted-by":"publisher","unstructured":"Dube M, Tastet O, Dufour C, Sannier G, Brassard N, Delgado GG, Pagliuzza A, Richard C, Nayrac M, Routy JP, Prat A. Spontaneous HIV expression during suppressive ART is associated with the magnitude and function of HIV-specific CD4+ and CD8+ T cells. Cell host & microbe. 2023;31(9):1507-22. https:\/\/doi.org\/10.1016\/j.chom.2023.08.006.","DOI":"10.1016\/j.chom.2023.08.006"},{"key":"9345_CR14","doi-asserted-by":"publisher","unstructured":"Takata H, Mitchell JL, Pacheco J, Pagliuzza A, Pinyakorn S, Buranapraditkun S, Sacdalan C, Leyre L, Nathanson S, Kakazu JC, Intasan J. An active HIV reservoir during ART is associated with maintenance of HIV-specific CD8+ T cell magnitude and short-lived differentiation status. Cell host microbe. 2023;31(9):1494-506. https:\/\/doi.org\/10.1016\/j.chom.2023.08.012.","DOI":"10.1016\/j.chom.2023.08.012"},{"key":"9345_CR15","doi-asserted-by":"crossref","unstructured":"Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic\u00a0immune activation in chronic HIV infection. Nat Med. 2006;12(12):1365\u201371.","DOI":"10.1038\/nm1511"},{"key":"9345_CR16","doi-asserted-by":"crossref","unstructured":"Clayton KL, Garcia V, Clements JE, Walker BD. HIV Infection of Macrophages: Implications for Pathogenesis and Cure. PAI. 2017;2(2):179.","DOI":"10.20411\/10.20411\/pai.v2i2.204"},{"key":"9345_CR17","doi-asserted-by":"crossref","unstructured":"Peng X, Isnard S, Lin J, Fombuena B, Bessissow T, Chomont N, et al. Differences in HIV burden in the inflamed and non-inflamed colon from a person living with HIV and ulcerative colitis. J Virus Erad. 2021;7(1):100033.","DOI":"10.1016\/j.jve.2021.100033"},{"key":"9345_CR18","doi-asserted-by":"crossref","unstructured":"Gosselin A, Wiche Salinas TR, Planas D, Wacleche VS, Zhang Y, Fromentin R, et al. HIV persists in CCR6+CD4+ T cells from colon and blood during antiretroviral therapy. AIDS. 2017;31(1):35\u201348.","DOI":"10.1097\/QAD.0000000000001309"},{"key":"9345_CR19","doi-asserted-by":"crossref","unstructured":"Gosselin A, Monteiro P, Chomont N, Diaz-Griffero F, Said EA, Fonseca S, et al. Peripheral Blood CCR4+CCR6+ and CXCR3+CCR6+ CD4+ T Cells Are Highly Permissive to HIV-1 Infection. J Immunol. 2010;184(3):1604\u201316.","DOI":"10.4049\/jimmunol.0903058"},{"key":"9345_CR20","doi-asserted-by":"crossref","unstructured":"Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol. 2012;10(9):655\u201366.","DOI":"10.1038\/nrmicro2848"},{"key":"9345_CR21","doi-asserted-by":"crossref","unstructured":"Ramendra R, Isnard S, Mehraj V, Chen J, Zhang Y, Finkelman M, et al. Circulating LPS and (1\u21923)-\u03b2-D-Glucan: A Folie \u00e0 Deux Contributing to HIV-Associated Immune Activation. Front Immunol. 2019;10:465.","DOI":"10.3389\/fimmu.2019.00465"},{"key":"9345_CR22","doi-asserted-by":"crossref","unstructured":"Mehraj V, Ramendra R, Isnard S, Dupuy FP, Ponte R, Chen J, et al. Circulating (1\u21923)-\u03b2-D-glucan Is Associated With Immune Activation During Human Immunodeficiency Virus Infection. Clin Infect Dis. 2020;70(2):232\u201341.","DOI":"10.1093\/cid\/ciz212"},{"key":"9345_CR23","doi-asserted-by":"crossref","unstructured":"Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15(8):893\u2013900.","DOI":"10.1038\/nm.1972"},{"key":"9345_CR24","doi-asserted-by":"crossref","unstructured":"Anh\u00ea FF, Varin TV, Le Barz M, Desjardins Y, Levy E, Roy D, et al. Gut Microbiota Dysbiosis in Obesity-Linked Metabolic Diseases and Prebiotic Potential of Polyphenol-Rich Extracts. Curr Obes Rep. 2015;4(4):389\u2013400.","DOI":"10.1007\/s13679-015-0172-9"},{"key":"9345_CR25","doi-asserted-by":"crossref","unstructured":"Cani PD. Human gut microbiome: hopes, threats and promises. Gut. 2018;67(9):1716\u201325.","DOI":"10.1136\/gutjnl-2018-316723"},{"key":"9345_CR26","doi-asserted-by":"crossref","unstructured":"Lu W, Feng Y, Jing F, Han Y, Lyu N, Liu F, et al. Association Between Gut Microbiota and CD4 Recovery in HIV-1 Infected Patients. Front Microbiol. 2018;9:1451.","DOI":"10.3389\/fmicb.2018.01451"},{"key":"9345_CR27","doi-asserted-by":"crossref","unstructured":"Borgognone A, Noguera-Julian M, Oriol B, No\u00ebl-Romas L, Ruiz-Riol M, Guill\u00e9n Y, et al. Gut microbiome signatures linked to HIV-1 reservoir size and viremia control. Microbiome. 2022;10(1):59.","DOI":"10.1186\/s40168-022-01247-6"},{"key":"9345_CR28","doi-asserted-by":"crossref","unstructured":"Planas D, Routy JP, Ancuta P. New Th17-specific therapeutic strategies for HIV remission. Current Opinion in HIV and AIDS. 2019;14(2):85\u201392.","DOI":"10.1097\/COH.0000000000000522"},{"key":"9345_CR29","doi-asserted-by":"crossref","unstructured":"Ouyang J, Isnard S, Lin J, Fombuena B, Peng X, Nair Parvathy S, et al. Treating From the Inside Out: Relevance of Fecal Microbiota Transplantation to Counteract Gut Damage in GVHD and HIV Infection. Front Med. 2020;7:421.","DOI":"10.3389\/fmed.2020.00421"},{"key":"9345_CR30","doi-asserted-by":"crossref","unstructured":"Andary CM, Al KF, Chmiel JA, Gibbons S, Daisley BA, Parvathy SN, et al. Dissecting mechanisms of fecal microbiota\u00a0transplantation efficacy in disease.\u00a0Trends Mol Med. 2024;30(3):209\u201322.","DOI":"10.1016\/j.molmed.2023.12.005"},{"key":"9345_CR31","doi-asserted-by":"crossref","unstructured":"Hensley-McBain T, Zevin AS, Manuzak J, Smith E, Gile J, Miller C, et al. Effects of Fecal Microbial Transplantation on Microbiome and Immunity in Simian Immunodeficiency Virus-Infected Macaques. Kirchhoff F, editor. J Virol. 2016;90(10):4981\u20139.","DOI":"10.1128\/JVI.00099-16"},{"key":"9345_CR32","doi-asserted-by":"crossref","unstructured":"Vujkovic-Cvijin I, Rutishauser RL, Pao M, Hunt PW, Lynch SV, McCune JM, et al. Limited engraftment of donor microbiome via one-time fecal microbial transplantation in treated HIV-infected individuals. Gut Microbes. 2017;8(5):440\u201350.","DOI":"10.1080\/19490976.2017.1334034"},{"key":"9345_CR33","doi-asserted-by":"crossref","unstructured":"Serrano-Villar S, Talavera-Rodr\u00edguez A, Gosalbes MJ, Madrid N, P\u00e9rez-Molina JA, Elliott RJ, et al. Fecal microbiota transplantation in HIV: A pilot placebo-controlled study. Nat Commun. 2021;12(1):1139.","DOI":"10.1038\/s41467-021-21472-1"},{"key":"9345_CR34","doi-asserted-by":"crossref","unstructured":"D\u00edaz-Garc\u00eda C, Moreno E, Talavera-Rodr\u00edguez A, Mart\u00edn-Fern\u00e1ndez L, Gonz\u00e1lez-Bod\u00ed S, Mart\u00edn-Pedraza L, et al. Fecal microbiota transplantation alters the proteomic landscape of inflammation in HIV: identifying bacterial drivers. Microbiome. 2024;12(1):214.","DOI":"10.1186\/s40168-024-01919-5"},{"key":"9345_CR35","doi-asserted-by":"crossref","unstructured":"Routy B, Lenehan JG, Miller WH, Jamal R, Messaoudene M, Daisley BA, et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nat Med. 2023;29(8):2121\u201332.","DOI":"10.1038\/s41591-023-02453-x"},{"key":"9345_CR36","doi-asserted-by":"crossref","unstructured":"Isnard S, Ramendra R, Dupuy FP, Lin J, Fombuena B, Kokinov N, et al. Plasma Levels of C-Type Lectin REG3\u03b1 and Gut Damage in People With Human Immunodeficiency Virus. J Infect Dis. 2020;221(1):110\u201321.","DOI":"10.1093\/infdis\/jiz423"},{"key":"9345_CR37","doi-asserted-by":"crossref","unstructured":"Webel A, Sattar A, Funderburg N, Kinley B, Longenecker C, Labbato D, et al. Alcohol and dietary factors associate with gut integrity and inflammation in HIV \u2010infected adults. HIV Medicine. 2017;18(6):402\u201311.","DOI":"10.1111\/hiv.12442"},{"key":"9345_CR38","doi-asserted-by":"crossref","unstructured":"Yan J, Ouyang J, Isnard S, Zhou X, Harypursat V, Routy JP, et al. Alcohol Use and Abuse Conspires With HIV Infection to Aggravate Intestinal Dysbiosis and Increase Microbial Translocation in People Living With HIV: A Review. Front Immunol. 2021;12:741658.","DOI":"10.3389\/fimmu.2021.741658"},{"key":"9345_CR39","doi-asserted-by":"crossref","unstructured":"Kao D, Roach B, Silva M, Beck P, Rioux K, Kaplan GG, et al. Effect of Oral Capsule\u2013 vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. JAMA. 2017;318(20):1985.","DOI":"10.1001\/jama.2017.17077"},{"key":"9345_CR40","doi-asserted-by":"crossref","unstructured":"Al KF, Craven LJ, Gibbons S, Parvathy SN, Wing AC, Graf C, et al. Fecal microbiota transplantation is safe and tolerable in patients with multiple sclerosis: A pilot randomized controlled trial. Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2022;8(2):20552173221086662.","DOI":"10.1177\/20552173221086662"},{"key":"9345_CR41","doi-asserted-by":"crossref","unstructured":"Craven L, Rahman A, Nair Parvathy S, Beaton M, Silverman J, Qumosani K, et al. Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial. Am JGastroenterol. 2020;115(7):1055\u201365.","DOI":"10.14309\/ajg.0000000000000661"},{"key":"9345_CR42","doi-asserted-by":"crossref","unstructured":"Craven LJ, Nair Parvathy S, Tat-Ko J, Burton JP, Silverman MS. Extended Screening Costs Associated With Selecting Donors for Fecal Microbiota Transplantation for Treatment of Metabolic Syndrome-Associated Diseases. Open Forum Infect Dis. 2017;4(4):ofx243.","DOI":"10.1093\/ofid\/ofx243"},{"key":"9345_CR43","doi-asserted-by":"crossref","unstructured":"Ninkov M, Schmerk CL, Moradizadeh M, Parvathy SN, Figueredo R, Burton JP, et al. Improved MAIT cell functions following\u00a0fecal microbiota transplantation for metastatic renal cell carcinoma. Cancer Immunol Immunother. 2023;72(5):1247\u201360.","DOI":"10.1007\/s00262-022-03329-8"},{"key":"9345_CR44","doi-asserted-by":"crossref","unstructured":"Routy JP, Isnard S, Mehraj V, Ostrowski M, Chomont N, Ancuta P, et al. Effect of metformin on the size of the HIV reservoir in non-diabetic ART-treated individuals: single-arm non-randomised Lilac pilot study protocol. BMJ Open. 2019;9(4):e028444.","DOI":"10.1136\/bmjopen-2018-028444"},{"key":"9345_CR45","doi-asserted-by":"crossref","unstructured":"Isnard S, Fombuena B, Ouyang J, Royston L, Lin J, Bu S, et al. Camu Camu effects on microbial translocation and systemic immune activation in ART-treated people living with HIV: protocol of the single-arm non-randomised Camu Camu prebiotic pilot study (CIHR\/CTN PT032). BMJ Open. 2022;12(1):e053081.","DOI":"10.1136\/bmjopen-2021-053081"},{"key":"9345_CR46","doi-asserted-by":"crossref","unstructured":"Mehraj V, Ghali P, Ramendra R, Costiniuk C, Lebouch\u00e9 B, Ponte R, et al. The evaluation of risk-benefit ratio for gut tissue sampling in HIV cure research.\u00a0J Virus Erad. 2017;3(4):212\u20137.","DOI":"10.1016\/S2055-6640(20)30316-2"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09345-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09345-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09345-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T12:39:10Z","timestamp":1768912750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-025-09345-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9345"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09345-0","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,13]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol (version 2.1, dated 11 November 2024) has been approved by the Research Ethics Board (REB) at McGill University Health Centre. All participants provide written informed consent prior to enrollment. Optional sub-study procedures (colon biopsies) require separate informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"All study participants consent to publication of the study results in aggregate form. No identifying information will be disclosed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"JPR has performed contract research and\/or served on Advisory Boards for Gilead Sciences, Merck, Abbvie, and ViiV Healthcare. BL is supported by a career award from Quebec\u2019s Ministry of Health for researchers in family medicine. BL has received consultancy fees and\/or honoraria from Gilead, Merck, and ViiV, and research funds from Gilead, Merck, and ViiV Healthcare, and support to attend educational conferences from ViiV Healthcare and Gilead. CTC is supported by a Fonds de recherche due Qu\u00e9bec-Sant\u00e9 Junior 2 career award. The other authors declare no competing interests. If any future competing interests arise during the course of the study or at the time of publication, they will be disclosed accordingly.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"52"}}